VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

Search

Medtronic PLC

Closed

SectorHealthcare

88.44 -1.53

Overview

Share price change

24h

Current

Min

88.2

Max

89.76

Key metrics

By Trading Economics

Income

32M

1.3B

Sales

-111M

8.3B

P/E

Sector Avg

27.479

73.239

EPS

1.39

Dividend yield

3.11

Profit margin

15.798

Employees

95,000

EBITDA

-40M

2.4B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+7.28% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.11%

3.06%

Next Earnings

22 May 2025

Next Dividend date

11 Apr 2025

Next Ex Dividend date

27 Jun 2025

Market Stats

By TradingEconomics

Market Cap

-5B

116B

Previous open

89.97

Previous close

88.44

News Sentiment

By Acuity

36%

64%

109 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Medtronic PLC Chart

Past performance is not a reliable indicator of future results.

Related News

18 Feb 2025, 12:24 UTC

Earnings

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

19 Nov 2024, 12:27 UTC

Earnings

Medtronic Narrows Fiscal Year Guidance as 2Q Tops Views

27 Feb 2025, 10:30 UTC

Top News

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18 Feb 2025, 11:47 UTC

Earnings

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18 Feb 2025, 11:46 UTC

Earnings

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

18 Feb 2025, 11:45 UTC

Earnings

Medtronic 3Q Adj EPS $1.39 >MDT

18 Feb 2025, 11:45 UTC

Earnings

Medtronic 3Q Neuroscience Portfolio Rev $2.46B >MDT

18 Feb 2025, 11:45 UTC

Earnings

Medtronic 3Q Net $1.29B >MDT

18 Feb 2025, 11:45 UTC

Earnings

Medtronic 3Q Diabetes Rev $694M >MDT

18 Feb 2025, 11:45 UTC

Earnings

Medtronic 3Q Medical Surgical Portfolio Rev $2.07B >MDT

18 Feb 2025, 11:45 UTC

Earnings

Medtronic 3Q Cardiovascular Portfolio Rev $3.04B >MDT

18 Feb 2025, 11:45 UTC

Earnings

Medtronic 3Q Organic Revenue Up 4.1% >MDT

18 Feb 2025, 11:45 UTC

Earnings

Medtronic 3Q EPS $1.01 >MDT

18 Feb 2025, 11:45 UTC

Earnings

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

18 Feb 2025, 11:45 UTC

Earnings

Medtronic 3Q Sales $8.29B >MDT

18 Feb 2025, 10:01 UTC

Earnings
Hot Stocks

Stocks to Watch Tuesday: Intel, Baidu, Constellation Brands -- WSJ

21 Jan 2025, 19:15 UTC

Top News

Medtronic Hires CFO From Renault -- Update

21 Jan 2025, 12:17 UTC

Top News

Medtronic Hires CFO From Renault

19 Nov 2024, 12:12 UTC

Earnings

Medtronic Narrows FY Guidance as 2Q Tops Views

19 Nov 2024, 11:46 UTC

Earnings

Medtronic Sees High-Single-Digit Adjusted EPS Growth in 2nd Half of FY25 >MDT

19 Nov 2024, 11:46 UTC

Earnings

Medtronic Narrows FY25 Organic Rev Growth View to 4.75%-5% From 4.5%-5% >MDT

19 Nov 2024, 11:45 UTC

Earnings

Medtronic 2Q Medical Surgical Portfolio Rev $2.13B >MDT

19 Nov 2024, 11:45 UTC

Earnings

Medtronic 2Q Adj EPS $1.26 >MDT

19 Nov 2024, 11:45 UTC

Earnings

Medtronic 2Q Diabetes Rev $686M >MDT

19 Nov 2024, 11:45 UTC

Earnings

Medtronic 2Q Neuroscience Portfolio Rev $2.45B >MDT

19 Nov 2024, 11:45 UTC

Earnings

Medtronic 2Q Net $1.27B >MDT

19 Nov 2024, 11:45 UTC

Earnings

Medtronic 2Q Organic Revenue Up 5.0% >MDT

19 Nov 2024, 11:45 UTC

Earnings

Medtronic 2Q Cardiovascular Portfolio Rev $3.1B >MDT

19 Nov 2024, 11:45 UTC

Earnings

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

19 Nov 2024, 11:45 UTC

Earnings

Medtronic 2Q Sales $8.4B >MDT

Peer Comparison

Price change

Medtronic PLC Forecast

Price Target

By TipRanks

7.28% upside

12 Months Forecast

Average 96.4 USD  7.28%

High 109 USD

Low 85 USD

Based on 19 Wall Street analysts offering 12 month price targets forMedtronic PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

9

Buy

9

Hold

1

Sell

Technical Score

By Trading Central

88.02 / 90.29Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

109 / 386 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.